相关实验视频
Updated: Jul 11, 2025
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
900
克洛皮多格雷尔诱导的血小板缺血:一种罕见的不良反应
Catarina Távora1, Joana Rodrigues Dos Santos1, Diogo Cruz1
1Department of Medicine, Cascais Hospital, Lisbon, Portugal.
European journal of case reports in internal medicine
|November 3, 2023
概括
克洛皮多格雷尔很少会导致免疫血栓塞缩性紫外线 (ITP). 对于那些对初始治疗没有反应,需要手术的患者,用血栓形成素受体激动剂 (TPO-RAs) 的二线治疗有效地增加了血小板计数.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 免疫性血栓性紫外线 (ITP) 是一种罕见但严重的副作用,与某些药物有关.
- 据报道,抗血小板药物克洛皮多格雷尔 (clopidogrel) 不常引起ITP.
- 在需要手术的患者中,ITP的管理带来了独特的挑战,特别是在类固醇耐药性的情况下.
研究的目的:
- 报告老年男性患者中因克洛皮多格雷尔诱发的严重ITP病例.
- 要突出二线治疗的疗效与血栓形成素受体激动剂 (TPO-RAs) 在需要选择性手术的克洛皮多格勒诱导ITP的患者.
- 强调考虑克洛皮多格雷尔作为ITP的潜在原因的重要性.
主要方法:
- 一个79岁的男性患者的病例报告.
- 详细描述临床表现,诊断和治疗过程.
- 关于克洛皮多格雷尔诱导的ITP和TPO-RA疗效的文献综述.
主要成果:
- 患者在开始用克洛皮多格雷尔治疗后出现严重的ITP.
- 最初用皮质类固醇和免疫球蛋白治疗是无效的.
- 用罗米普洛司姆 (TPO-RA) 的二线治疗导致血小板数显著增加,使选择性手术成为可能.
结论:
- 克洛皮多格雷尔是免疫性血栓缩紫外线的潜在原因,因此在隔离性血栓缩的差异诊断中需要考虑它.
- 血栓形成素受体激动剂是ITP的有效二线治疗方法,特别是在对类固醇反应差或需要选择性手术的患者中.
- 早期考虑TPO-RAs可以改善耐火性ITP患者的治疗结果.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
535
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
535
01:24Disorders of Hemostasis
957
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
957
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
719
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
719
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10